These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27886397)

  • 1. Telomerase and N-Cadherin Differential Importance in Adrenocortical Cancers and Adenomas.
    Pereira SS; Máximo V; Coelho R; Batista R; Soares P; Guerreiro SG; Sobrinho-Simões M; Monteiro MP; Pignatelli D
    J Cell Biochem; 2017 Aug; 118(8):2064-2071. PubMed ID: 27886397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors.
    Fonseca AL; Kugelberg J; Starker LF; Scholl U; Choi M; Hellman P; Åkerström G; Westin G; Lifton RP; Björklund P; Carling T
    Genes Chromosomes Cancer; 2012 Oct; 51(10):949-60. PubMed ID: 22733721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TERT promoter hypermethylation is associated with poor prognosis in adrenocortical carcinoma.
    Svahn F; Paulsson JO; Stenman A; Fotouhi O; Mu N; Murtha TD; Korah R; Carling T; Bäckdahl M; Wang N; Juhlin CC; Larsson C
    Int J Mol Med; 2018 Sep; 42(3):1675-1683. PubMed ID: 29956721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions.
    Blanes A; Diaz-Cano SJ
    Hum Pathol; 2006 Oct; 37(10):1295-303. PubMed ID: 16949934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis and Lymphangiogenesis in the Adrenocortical Tumors.
    Pereira SS; Costa MM; Guerreiro SG; Monteiro MP; Pignatelli D
    Pathol Oncol Res; 2018 Jul; 24(3):689-693. PubMed ID: 28695321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for epithelial-mesenchymal transition in adrenocortical tumors?
    Bulzico D; Faria PAS; Maia CB; de Paula MP; Torres DC; Ferreira GM; Pires BRB; Hassan R; Abdelhay E; Vaisman M; Vieira Neto L
    Endocrine; 2017 Nov; 58(2):276-288. PubMed ID: 28887601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas.
    Mannelli M; Gelmini S; Arnaldi G; Becherini L; Bemporad D; Crescioli C; Pazzagli M; Mantero F; Serio M; Orlando C
    J Clin Endocrinol Metab; 2000 Jan; 85(1):468-70. PubMed ID: 10634426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic silencing of RASSF1A deregulates cytoskeleton and promotes malignant behavior of adrenocortical carcinoma.
    Korah R; Healy JM; Kunstman JW; Fonseca AL; Ameri AH; Prasad ML; Carling T
    Mol Cancer; 2013 Aug; 12():87. PubMed ID: 23915220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas.
    Gupta S; Won H; Chadalavada K; Nanjangud GJ; Chen YB; Al-Ahmadie HA; Fine SW; Sirintrapun SJ; Strong VE; Raj N; Lagunes DR; Vanderbilt CM; Berger MF; Ladanyi M; Dogan S; Tickoo SK; Reuter VE; Gopalan A
    Endocr Pathol; 2022 Jun; 33(2):304-314. PubMed ID: 34549366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma.
    Romero Arenas MA; Whitsett TG; Aronova A; Henderson SA; LoBello J; Habra MA; Grubbs EG; Lee JE; Sircar K; Zarnegar R; Scognamiglio T; Fahey TJ; Perrier ND; Demeure MJ
    Ann Surg Oncol; 2018 Mar; 25(3):801-807. PubMed ID: 29218429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis regulating genes, bcl-2 and bax, and human telomerase reverse transcriptase messenger RNA expression in adrenal tumors: possible diagnostic and prognostic importance.
    Kanauchi H; Wada N; Clark OH; Duh QY
    Surgery; 2002 Dec; 132(6):1021-6; discussion 1026-7. PubMed ID: 12490850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors.
    Sbiera S; Schmull S; Assie G; Voelker HU; Kraus L; Beyer M; Ragazzon B; Beuschlein F; Willenberg HS; Hahner S; Saeger W; Bertherat J; Allolio B; Fassnacht M
    J Clin Endocrinol Metab; 2010 Oct; 95(10):E161-71. PubMed ID: 20660055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
    Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcription factors GATA-6, SF-1, and cell proliferation in human adrenocortical tumors.
    Kiiveri S; Liu J; Arola J; Heikkilä P; Kuulasmaa T; Lehtonen E; Voutilainen R; Heikinheimo M
    Mol Cell Endocrinol; 2005 Apr; 233(1-2):47-56. PubMed ID: 15767045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower expression of ATM and gene deletion is more frequent in adrenocortical carcinomas than adrenocortical adenomas.
    Ye J; Qi Y; Wang W; Sun F; Wei Q; Su T; Zhou W; Jiang Y; Yuan W; Cai J; Cui B; Ning G
    Endocrine; 2012 Jun; 41(3):479-86. PubMed ID: 22311173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.